Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

NCT05329545 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Study Terminated by Sponsor

Conditions

High Grade Serous Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

DRUG: Upifitimab rilsodotin
OTHER: Placebo

Sponsor

Mersana Therapeutics

Collaborators

[object Object]
[object Object]